XenaCare receives ‘Best New Product’ award at conference

DELRAY BEACH, Fla. XenaCare Holdings on Monday announced that its stage 2 pain reliever, Cobroxin, has won the award for “Best New Product,” sponsored by Drug Store News, at the recent ECRM Health held in Miami.

“It is an honor to have Cobroxin chosen as the best new product at ECRM,” stated Frank Rizzo, president of XenaCare. “This award … supports our belief that Cobroxin will soon become the preferred alternative to current opiate and acetaminophen-based analgesics,” he concluded.

Retailer attendees nominate and vote on “Best New Product” at the show.

Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Recently, XenaCare Holdings was awarded the exclusive license for marketing and distributing Cobroxin within the United States.

As part of Drug Store News’ sponsorship of the award, XenaCare Holdings will receive a full-page advertisement in an upcoming issue of Drug Store News.